Celina Dubin's research while affiliated with Icahn School of Medicine at Mount Sinai and other places

Publications (17)

Article
Background In the SARS-CoV-2/COVID-19 pandemic, we need to understand the impact of immunomodulatory medications on COVID-19 symptom severity in patients with inflammatory diseases, including the Type 2/Th2 polarized skin disease, atopic dermatitis/AD. Objective Since it is believed that Type 1/Th1immunity controls viral infections, and that there...
Article
Introduction Atopic dermatitis (AD) is the most common inflammatory skin disease. It has a complex pathophysiology, with a combination of immune dysregulation and intrinsic barrier defects driving cutaneous inflammation and allergic symptomatology. The IL-4, IL-13, and IL-31 inflammatory pathways have been identified as hallmark features in the pat...
Article
Background Frontal fibrosing alopecia/FFA is a progressive, scarring alopecia of the frontotemporal scalp, and poses a substantial burden on quality of life. Largescale global profiling of FFA is lacking, preventing the development of effective therapeutics. Objective To characterize FFA compared to normal and alopecia areata/AA using broad molecu...
Article
Background Atopic dermatitis/AD is a common disease, with particularly high prevalence seen in Africa. It is increasingly recognized that AD patients of different ethnic backgrounds have unique molecular signatures in skin, potentially accounting for treatment response variations. However, the skin profile of AD patients from Africa is unknown, hin...
Article
Background Alopecia areata (AA) is characterized by immunedysregulation in both scalp and blood, but a largescale approach establishing biomarkersof AA incorporating both scalp tissue and serum compartments is lacking. We aimed to characterize thetranscriptomicsignature of AA lesional and nonlesional scalp compared to healthy scalp and determine it...
Article
Full-text available
Dubin C, Del Duca E, Guttman-Yassky E. Ther Clin Risk Manag. 2020;16:1319– 1332. The authors have advised the drug, ARQ-252, was misnamed in the paper as roflumilast (which is called ARQ-151 and ARQ-154 by the manufacturer). The drug named ARQ-252 by the manufacturer should instead be classified as a JAK1 inhibitor in the paper. On page 1320, CHE T...
Article
Full-text available
Celina Dubin,1 Ester Del Duca,1,2 Emma Guttman-Yassky1,3 1Department of Dermatology, Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA; 2Department of Dermatology, University of Magna Graecia, Catanzaro, Italy; 3Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY, USA...
Article
Context: Skin sensitivity may be best defined as self-reported intolerance to application of skincare products. It is commonly believed that individuals with darker skin are generally less sensitive, while those lighter skin are more sensitive. However, there is little objective data correlating sensitivity with skin type or with objective measures...
Article
Background Although there is increased understanding of the alopecia areata/AA pathogenesis based on studies in scalp tissues, little is known about its systemic profile. Objective To evaluate the blood proteomic signature of AA and determine biomarkers associated with increased disease severity. Methods In a cross-sectional study, we assessed 35...
Article
Full-text available
This is the first study that objectively compares the molecular cutaneous improvement with different treatments in AD and may facilitate personalized medicine by identifying the best treatments for individual phenotypes, based on immune/barrier profiles.
Article
Background: Moderate-to-severe atopic dermatitis (AD) has been associated with significant disease burden and systemic abnormalities and often requires systemic treatments. Currently, safe and effective oral systemic treatments for moderate-to-severe AD are not yet available. ASN002 is an oral inhibitor of the Janus kinase/spleen tyrosine kinase s...

Citations

... 8 Furthermore, the elevation of Th2 cytokines in serum of COVID-19 patients was reported repeatedly specially during the cytokine storm. 9 Dupilumab is a fully humanized monoclonal antibody that targets and blocks interleukin-4 (IL-4) receptor-α, which is shared by both IL-4 and IL-13. Hence the latter two interleukins have crucial role in the pathogenesis of AD 10 ; in this context dupilumab was the first FDA approved immunomodulatory medication to treat moderate to severe AD. 1,9,10 IN March 2020 the European Task Force stated that dupilumab does not seem to increase the risk of viral infections and may be considered as a better option than immunosuppressant in the management of AD, 11 many studies conducted later to examine the safety of dupilumab in AD patients during the COVID-19 pandemic. ...
... Previous research has established that the loss of FLG exhibited enhanced allergeninduced inflammation, and in cases without inflammation, mutations were found to induce alterations in differential protein expression of kallikrein (KLK7), peptidylprolyl isomerase A (PPIA), and cofilin-1 (CFL1) [31]. Another important aspect of AD development is the expression of Th2 cytokines IL-4 [32], IL-5, and IL-13 in modulating inflammation [33]. Mice with overexpression of Th2 cytokines have also been used to elucidate their immune cell recruitment and activation functions. ...
... T helper 2 (T H 2), T H 22, T H 17 and T H 1 pathways can be differently overexpressed. 19 One study revealed that, in Tanzanian people with AD, T H 1-related and T H 17-related markers may be upregulated compared to controls. 19 ...
... Some articles stated that even children with the same allergic diseases or healthy children have different molecular features among different age groups. 47,48 Therefore, results might be different from the studies conducted on different age groups, and detailed research is needed in each age group in a longterm future study. Fourth, these results might be different from studies that focus only on children who had already developed an allergic disease such as hospital-based medical chart data. ...
... CCL-17, CCL-18, and CCL-22, all dendrocyte-activated chemokines, are differentially pronounced in AD (43, 54,64,83,115,[129][130][131][132]. Interestingly, IL-4 activates different antigen-presenting cells, contributing to this observation. ...
... AA is associated, however, with several immune abnormalities, some non-selective while others appear to be more specific and point to an immune abnormality that targets a component(s) of the HF, especially when in the anagen phase of the hair growth cycle. Still, AA may also have features of systemic disease, as is characterized by frequent involvement of other tissues that so far include nails, eyes, and heart (6)(7)(8)(9). AA is most readily seen on areas of the body with the highest proportion of HF in the growth phase of the hair cycle (called anagen) e.g., scalp and beard. However, it may appear on any hair-bearing sites (10,11). ...
... Существует значительная неудовлетворенная потребность в эффективных терапевтических стратегиях долгосрочного контроля за течением хронической экземы. Согласно статистическим данным после 5 лет лечения различными топическими средствами примерно 65% пациентов имеют непрерывно рецидивирующее течение [4,23,24]. Топические глюкокортикостероиды (ГКС) на сегодняшний день являются средством выбора для лечения хронической экземы кистей рук [22][23][24][25]. Однако длительное применение топических ГКС может препятствовать восстановлению рогового слоя эпидермиса за счет нарушения синтеза липидов и вызывать атрофию кожи [26]. ...
... Globally, as much as 71% of the general adult population reports having sensitive skin to some degree, while 40% individuals report having moderate or very sensitive skin [6]. Patient's self-perception of skin sensitivity has been found as a likely indicator of true sensitivity measured instrumentally, and it may occur with similar prevalence across all Fitzpatrick skin types [7]. Epidemiological studies have also shown that these symptoms are more frequent on the face, where the skin is more exposed and nerve density is higher [8]. ...
... Conversely, another matched cohort study conducted in the USA found a decreased risk for stroke and a trend toward a decreased risk for AMI in patients with AA [31]. Studies have found higher levels of cardiovascular biomarkers in the serum of patients with AA compared with controls, suggesting they may be at an increased risk for CVD [32][33][34]. Further study is needed to evaluate the risk of CVD in patients with AA. ...
... We computed enrichment scores for Th1 and Th2 immune pathways (Glickman et al., 2020) by gene set variation analysis (Hanzelmann et al., 2013), and modeled the Th2/Th1 balance as the difference between Th2 and Th1 enrichment scores. ...